Mankind Pharma Share Price Slips 4% Despite Q3 FY26 Earnings Net Profit Growth

Mankind Pharma share price (NSE: MANKIND) declined nearly 4% on Wednesday, marking the stock’s biggest single-day drop in over 8 months. The fall came even after the company reported steady third-quarter earnings for FY26.

The stock touched an intraday low of around ₹2,080 and underperformed the broader market, which was largely flat during the session.

Mankind Pharma Q3 FY26 Earnings Results: Profit and Revenue Show Growth

Mankind Pharma reported a profit after tax (PAT) of ₹414 crore for Q3FY26, compared with ₹378 crore in the same quarter last year. Revenue from operations grew 11.5% year-on-year to ₹3,567 crore.

The domestic business, which contributes about 85% of total revenue, grew 11.1%, driven mainly by strong demand in chronic therapies such as cardiac and anti-diabetes drugs.

Consumer Healthcare Sees Steady Demand

The company’s consumer healthcare segment posted a 5.2% year-on-year growth. Brands like Gas-O-Fast, Manforce, and Ova saw healthy secondary sales during the quarter, supporting overall performance.

About Mankind Pharma

Mankind Pharma is a global pharmaceutical and healthcare company based in Delhi. It offers a wide range of products across key treatment areas, including antibiotics, gastrointestinal care, heart-related therapies, skin treatments, and medicines for erectile dysfunction.

Conclusion

Mankind Pharma’s Q3 performance shows steady profit and revenue growth, but investors remain cautious due to slow organic growth and execution challenges. The pace of recovery in key therapies and integration benefits will be closely watched going forward.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.